CMPS COMPASS Pathways plc Quick Ratio

This daily price chart for COMPASS Pathways plc (CMPS) on GURU.Markets, where the indicator stands at 1.24, is tied to the final test results of the COMP360 drug for treatment-resistant depression and FDA support. The business currently relies on the development of psilocybin-based therapies and remains in an investment stage without current profits. Meanwhile, COMPASS Pathways plc retains top experts due to its humanitarian mission.

CMPS: Compass Pathways Intermediate Coverage Ratio 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for compasspathways.com (CMPS)

- market value and analyst target forecast:

Price Chart Compass Pathways|CMPS - Consensus Target

- market capitalization data:

Market Capitalization Compass Pathways|CMPS - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value per Share COMPASS Pathways|CMPS - Accounting Value of Company|Market Value to Book Value Ratio compasspathways.com|CMPS - Total Asset Value of Company

- debt and liquidity data:

- earnings and valuation multiples information:

CMPS - Company Net Income

Comprehensive company analysis:Compass Pathways - CMPS

Manufactured product of COMPASS Pathways PLC

The quick ratio measures a company's ability to settle short-term debts using its most liquid assets, completely excluding inventory. An investor analyzes the quick ratio time series to identify hidden cash gaps and assess capital quality. A stable ratio confirms the issuer's solvency. For COMPASS Pathways plc (CMPS), this is critical when financing costly psilocybin development and acquiring new patents through M&A.

Main competitors